多剤耐性結核治療薬市場：製品、投与方法、流通チャネル別-世界予測2024-2030年

多剤耐性結核治療薬市場規模は、2023年に2億8,100万米ドルと推定され、2024年には3億1,132万米ドルに達し、CAGR 11.14％で2030年には5億8,862万米ドルに達すると予測されます。

多剤耐性結核（MDR-TB）治療薬とは、少なくとも2種類の最も強力な抗結核薬であるイソニアジドとリファンピシンに対して耐性を獲得した結核菌と闘うために採用される治療戦略と薬剤を指します。これらの薬剤は標準的な結核治療の要であり、これらに対する耐性は治療プロセスを著しく複雑にするため、代替薬の使用が必要となります。MDR-TB治療では通常、治療期間が長くなり、多くの場合24ヵ月に及ぶ。また、薬剤感受性の結核に使用される第一選択薬に比べ、高価で効果が低く、副作用のリスクが高い第二選択薬を使用することになります。特に発展途上諸国における結核罹患率の増加は、効果的なMDR-TB治療に対する需要の高まりに直結しています。さらに、世界各国の政府や非政府組織による資金援助、啓発キャンペーン、支援政策の増加が市場成長に大きく寄与しています。しかし、より効果的な新薬の価格が高騰しているため、低所得国でのアクセスが制限され、市場成長に直接的な影響を与えています。また、広範囲に薬剤耐性を持つ結核菌の進化が大きな障害となっており、継続的な研究開発が必要となっています。さらに、薬剤開発と診断技術の革新により、MDR-TB治療の有効性とアクセシビリティが向上しています。

提供多剤耐性結核を治療する革新的な治療法の開発を後押しする継続的研究活動

MDR-TB治療薬は、最も強力な結核治療薬であるイソニアジドとリファンピンに少なくとも耐性を持つ結核菌株を治療するために設計された様々な抗菌薬で構成されています。ベダキリンの投薬は、MDR-TB治療における重要な進歩です。ベダキリンは、結核菌がエネルギーを生成するのに必要な酵素を阻害することによって作用し、結核菌を効果的に飢餓状態にして死滅させる。デラマニドは、細菌の細胞壁の重要な構成要素であるマイコール酸の合成を阻害することにより、結核の原因菌であるマイコバクテリアを標的とします。この阻害により細菌は死滅します。レボフロキサシンとモキシフロキサシンはフルオロキノロン系と呼ばれるクラスに属し、広域スペクトル抗生物質です。レボフロキサシンとモキシフロキサシンは、フルオロキノロン系と呼ばれる種類に属し、幅広いスペクトルを持つ抗生物質です。レボフロキサシンとモキシフロキサシンは、細菌DNAの複製、転写、修復、組換えに重要なDNAジャイレースとトポイソメラーゼIV酵素を阻害することにより作用し、細菌細胞を死滅させる。プレトマニドは結核に対する新しい治療薬のひとつです。プレトマニドは通常、ベダキリンとリネゾリドを含む3剤併用レジメン（BPaL）の一部として使用され、特に広範囲薬剤耐性結核の治療に用いられます。MDR-TB治療は薬物療法にとどまらず、患者の包括的な健康ニーズに対応する支持療法も取り入れています。

流通チャネル：緊密な医療監視を提供するオフライン流通チャネルの重要性の高まり

病院薬局は、主要なオフライン・チャネルの一つです。病院薬局は病院内または病院に隣接しており、入院患者や多くの場合、外来患者にも直接薬を提供しています。MDR-TBのような、綿密な医学的管理が必要な多面的疾患では、病院薬局は重要な役割を果たします。処方された治療薬を即座に入手できるようにし、治療プロセスを合理化します。病院薬剤師は、患者に薬剤レジメンを助言・管理する上で極めて重要であり、MDR-TB治療の複雑な要件が十分に満たされていることを保証します。小売薬局は病院とは独立して運営されており、一般の人々にとってより身近な存在です。小売薬局は地域社会にあり、患者が処方された薬を入手するのに便利な場所となっています。小売薬局は、MDR-結核治療薬の調剤を含め、より広範なヘルスケアニーズに対応しています。デジタル技術の始まりにより、オンライン薬局の時代が到来し、MDR-TB治療薬などの流通チャネルとして成長しています。このプラットフォームでは、患者やその介護者がインターネット経由で薬を注文し、自宅に直接配送することができます。この流通形態は、遠隔地に住む患者や、従来の薬局店舗へのアクセスが困難な患者にとって特に有益です。オンライン薬局はまた、プライバシーが守られ、簡単で、時にはより幅広い製品にアクセスでき、より良い価格設定になる可能性があるという利点もあります。

地域別インサイト

米国とカナダは、MDR-TBとの戦いにおいて南北アメリカを代表する国です。これらの国の罹患率はアジア太平洋地域やEMEA地域と比べると比較的低いもの、異なる課題や消費者のニーズが浮き彫りになっています。米国では、革新的な治療法の市場投入を目指し、多額の研究資金と特許申請に裏打ちされた高度な診断技術の統合と新規治療薬の開発に重点が置かれています。EU諸国では、MDR-TBに対するアプローチとして、高度なヘルスケア・インフラ、強固な公衆衛生政策、研究イニシアチブを組み合わせています。早期発見、個別化医療、新薬とレジメンの治療プロトコールへの組み込みが重視されています。消費者の行動は、ヘルスケアシステムに対する高い信頼と、ワクチン接種や予防措置への参加意欲を特徴としています。中東は、報告の質やヘルスケアサービスへのアクセスにばらつきがあるなど、独自の課題に直面しています。ヘルスケアシステムの強化、診断精度の向上、一般市民の意識向上に向けた取り組みが集中的に行われています。中国、日本、インドは、多剤耐性結核（MDR-TB）の影響を大きく受けているアジア太平洋地域の主要国です。この地域は罹患率が高く、効果的な治療薬に対する大きな需要につながっています。これらの国々における消費者のニーズは、アクセスしやすく、手頃な価格で、効率的な治療オプションの緊急の必要性によってもたらされています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは多剤耐性結核治療薬市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、多剤耐性結核治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.多剤耐性結核治療薬市場の市場規模および予測は？

2.多剤耐性結核治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.多剤耐性結核治療薬市場の技術動向と規制枠組みは？

4.多剤耐性結核治療薬市場における主要ベンダーの市場シェアは？

5.多剤耐性結核治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で結核の蔓延が増加
    • 早期発見と個別化医療への重点が高まっている
    • 新薬開発に向けた研究開発活動の強化
  • 抑制要因
    • MDR薬の高コストと限られた償還オプション
  • 機会
    • 政府機関による結核啓発活動の強化
    • 診断手順における技術的進歩
  • 課題
    • 多剤耐性結核の治療に伴う複雑さ
• 市場セグメンテーション分析
  • 提供内容：多剤耐性結核を治療するための革新的な治療法の開発を促進する継続的な調査活動
  • 流通チャネル：綿密な医療監視を提供するオフライン流通チャネルの重要性が高まっている
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 多剤耐性結核治療薬市場：提供別

• 薬
• 治療法

第7章 多剤耐性結核治療薬市場投与方法別

• 注射薬
• 経口薬

第8章 多剤耐性結核治療薬市場：流通チャネル別

• オフライン
• オンライン

第9章 南北アメリカの多剤耐性結核治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の多剤耐性結核治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの多剤耐性結核治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 戦略的パートナーシップを通じて画期的なDR-TB治療へのアクセスを世界的に拡大
  • 多剤耐性結核に対する世界の戦いに画期的進展：低・中所得国でのアクセス向上のためベダキリンの特許を免除
  • アズトレオナム-アビバクタムの臨床的成功によりグラム陰性細菌感染症と闘う画期的な進歩
• 戦略分析と提言

第13章 競争力のあるポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET DYNAMICS
• FIGURE 7. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY BEDAQUILINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY BEDAQUILINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DELAMANID, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DELAMANID, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LEVOFLOXACIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LEVOFLOXACIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MOXIFLOXACIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MOXIFLOXACIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY PRETOMANID, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY PRETOMANID, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 44. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 45. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 46. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 47. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 48. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 49. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 50. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 51. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 52. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 53. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 54. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 55. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 56. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 57. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 58. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 59. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 60. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 61. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 62. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 63. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 64. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 65. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 66. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 67. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 68. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 69. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 70. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 71. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 72. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 73. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 74. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 75. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 76. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 77. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 78. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 79. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 80. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 81. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 82. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 83. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 84. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 85. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 86. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 87. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 88. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 89. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 90. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 91. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 92. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 93. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 94. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 95. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 96. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 97. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 98. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 99. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 100. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 101. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 102. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 103. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 104. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 105. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 106. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 107. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 108. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 110. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 112. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 114. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 116. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 118. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 119. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 120. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 121. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 122. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 123. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 124. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 125. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 126. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 127. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 128. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 129. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 130. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 131. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 132. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 133. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 134. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 135. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 136. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 137. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 138. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 139. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 140. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 141. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 142. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 143. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 144. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 145. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 146. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 147. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 148. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 149. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 150. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 151. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 152. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 153. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 154. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 155. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 156. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 157. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 158. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 159. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 160. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 161. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 162. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 163. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 164. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 165. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 166. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 167. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 168. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 169. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 170. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 171. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 172. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 173. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 174. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 175. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 176. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 177. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 178. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 179. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 180. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 181. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 182. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 183. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 184. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 185. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 186. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 187. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 188. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 189. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 190. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 191. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 192. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 193. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 194. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 195. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 196. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 197. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 198. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 199. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 200. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 201. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 202. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 203. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 204. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 205. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 206. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 207. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 208. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 209. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 210. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 211. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 212. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 213. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 214. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 215. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 216. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 217. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 218. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 219. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 220. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 221. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 222. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 223. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 224. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 225. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 226. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 227. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 228. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 229. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 230. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 231. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 232. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 233. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 234. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 235. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 236. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 237. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 238. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 239. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 240. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 251. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 252. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 253. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 254. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 255. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 256. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 257. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 258. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 259. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 260. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 261. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 262. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 263. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
• TABLE 264. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
• TABLE 265. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 266. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 267. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 268. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 269. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)

TABL

[186 Pages Report] The Multidrug-resistant Tuberculosis Therapeutics Market size was estimated at USD 281.00 million in 2023 and expected to reach USD 311.32 million in 2024, at a CAGR 11.14% to reach USD 588.62 million by 2030.

Multidrug-resistant tuberculosis (MDR-TB) therapeutics refers to the treatment strategies and medications employed to combat tuberculosis (TB) strains that have developed resistance to at least the two most potent anti-tuberculosis drugs, isoniazid and rifampicin. These drugs are the cornerstone of standard tuberculosis treatment, and resistance to them complicates the treatment process significantly, necessitating the use of alternative medications. MDR-TB therapeutics typically involve a longer treatment duration, often lasting up to 24 months, and the use of second-line drugs, which can be more expensive, less effective, and carry a higher risk of side effects compared to the first-line drugs used for drug-sensitive TB. The rising incidences of tuberculosis, particularly in developing countries, directly correlate with heightened demand for effective MDR-TB treatments. Moreover, increased funding, awareness campaigns, and supportive policies from governments and non-government organizations worldwide have significantly contributed to market growth. However, the elevated cost of newer, more effective drugs limits access in low-income countries, directly impacting market growth. The evolution of extensively drug-resistant TB strains poses a substantial hurdle, necessitating continuous research and development efforts. Furthermore, innovations in drug development and diagnostic technologies have enhanced the efficacy and accessibility of MDR-TB treatments.

Offering: Ongoing research activities boosting the development of innovative therapies to treat multidrug-resistant tuberculosis

Medication for MDR-TB comprises various antibacterial drugs designed to treat TB strains resistant to at least isoniazid and rifampin, the two most potent tuberculosis drugs. Bedaquiline medication represents a significant advancement in the treatment of MDR-TB. Bedaquiline works by inhibiting an enzyme the TB bacteria require to generate energy, effectively starving and killing the bacteria. Delamanid targets the mycobacteria causing TB by inhibiting mycolic acid synthesis, a crucial component of the bacterial cell wall. This disruption leads to the death of the bacteria. Levofloxacin and Moxifloxacin drugs belong to a class called fluoroquinolones, which are broad-spectrum antibiotics. They have been found effective in treating TB strains that have become resistant to first-line anti-TB drugs. Levofloxacin and Moxifloxacin work by inhibiting the DNA gyrase and topoisomerase IV enzymes, which are crucial for replication, transcription, repair, and recombination of bacterial DNA, thereby leading to bacterial cell death. Pretomanid medication is one of the newer additions to the arsenal against TB. Pretomanid is typically used as part of a three-drug regimen (BPaL) that includes Bedaquiline and Linezolid, specifically for treating extensively drug-resistant TB. MDR-TB therapies extend beyond medication, incorporating supportive treatments that address the comprehensive health needs of patients.

Distribution Channel: Growing significance of offline distribution channel as it provide close medical supervision

Hospital pharmacies are one of the primary offline channels. These are located within or adjacent to a hospital, where they provide medications directly to the in-patients and, in many instances, to out-patients as well. For multifaceted diseases such as MDR-TB, which require close medical supervision, hospital pharmacies play a critical role. They ensure the immediate availability of prescribed therapeutics, streamlining the treatment process. Hospital pharmacists are pivotal in advising and managing the drug regimen for patients, ensuring that the intricate requirements of MDR-TB therapy are adequately met. Retail pharmacies operate independently of hospital settings and are more accessible to the general public. They are located within communities, serving as a convenient point for patients to access their prescribed medications. Retail pharmacies cater to a broader spectrum of healthcare needs, including the dispensation of MDR-TB drugs. The beginning of digital technology has ushered in the era of online pharmacies, a growing distribution channel for MDR-TB therapeutics, among others. This platform allows patients or their caregivers to order medications via the Internet, which are then delivered directly to their homes. This mode of distribution is particularly beneficial for patients residing in remote areas or those who have difficulty accessing traditional pharmacy outlets. Online pharmacies also offer the advantage of privacy, ease, and sometimes access to a wider range of products and potentially better pricing.

Regional Insights

The United States and Canada represent the Americas in the battle against MDR-TB. Though the incidence rates in these countries are relatively lower compared to the Asia Pacific and EMEA regions, they highlight a different set of challenges and consumer needs. In the United States, the focus is on the integration of advanced diagnostic techniques and the development of novel therapeutics backed by significant research funding and patent filings that aim to bring innovative treatments to the market. In the EU countries, the approach towards MDR-TB involves a combination of advanced healthcare infrastructure, robust public health policies, and research initiatives. The emphasis is on early detection, personalized medicine, and the integration of new drugs and regimens into treatment protocols. Consumer behavior is characterized by a high level of trust in the healthcare system and a willingness to participate in vaccination and preventive measures. The Middle East faces unique challenges, including variable reporting quality and access to healthcare services. Efforts are concentrated on strengthening healthcare systems, improving diagnostic accuracy, and increasing public awareness. China, Japan, and India are key countries in the Asia Pacific region significantly impacted by multidrug-resistant tuberculosis (MDR-TB). This region witnesses a high incidence rate, contributing to a considerable demand for effective therapeutics. Consumer needs in these countries are driven by the urgent necessity for accessible, affordable, and efficient treatment options.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Multidrug-resistant Tuberculosis Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Multidrug-resistant Tuberculosis Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Multidrug-resistant Tuberculosis Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abcam Limited, Daiichi Sankyo Co., Ltd., Endo International Plc, Johnson & Johnson Services Inc., Lupin Limited, Macleods Pharmaceuticals Ltd., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi SA, and Santen Pharmaceutical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Multidrug-resistant Tuberculosis Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Offering
  • Medication
    • Bedaquiline
    • Delamanid
    • Levofloxacin
    • Moxifloxacin
    • Pretomanid

• Therapies

• Mode of Administration
  • Injectable Medications
  • Oral Medications

• Distribution Channel
  • Offline
    • Hospitals Pharmacies
    • Retail Pharmacies

• Online

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Multidrug-resistant Tuberculosis Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Multidrug-resistant Tuberculosis Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Multidrug-resistant Tuberculosis Therapeutics Market?

4. What is the market share of the leading vendors in the Multidrug-resistant Tuberculosis Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Multidrug-resistant Tuberculosis Therapeutics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of tuberculosis across the globe
    • 5.1.1.2. Growing emphasis is on early detection and personalized medicine
    • 5.1.1.3. Increasing research & development activities for new drug development
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of MDR drugs coupled with the limited reimbursement options
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing initiative from government organization for tuberculosis awareness
    • 5.1.3.2. Technological advancement in the diagnostics procedures
  • 5.1.4. Challenges
    • 5.1.4.1. Complexities associated with the treatment of multidrug-resistant tuberculosis
• 5.2. Market Segmentation Analysis
  • 5.2.1. Offering: Ongoing research activities boosting the development of innovative therapies to treat multidrug-resistant tuberculosis
  • 5.2.2. Distribution Channel: Growing significance of offline distribution channel as it provide close medical supervision
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Multidrug-resistant Tuberculosis Therapeutics Market, by Offering

• 6.1. Introduction
• 6.2. Medication
• 6.3. Therapies

7. Multidrug-resistant Tuberculosis Therapeutics Market, by Mode of Administration

• 7.1. Introduction
• 7.2. Injectable Medications
• 7.3. Oral Medications

8. Multidrug-resistant Tuberculosis Therapeutics Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Offline
• 8.3. Online

9. Americas Multidrug-resistant Tuberculosis Therapeutics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Multidrug-resistant Tuberculosis Therapeutics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Multidrug-resistant Tuberculosis Therapeutics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Expanding Global Access to Groundbreaking DR-TB Treatment Through Strategic Partnerships
  • 12.3.2. Breakthrough in Global Fight Against MDR TB: Bedaquiline Patents Waived to Enhance Access in Low- and Middle-Income Countries
  • 12.3.3. Breakthrough in Combating Gram-Negative Bacterial Infections with Aztreonam-Avibactam's Clinical Triumphs
• 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio